The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Neurological University Hospital, St. Josef Hospital, Bochum, West Germany.
H
H
Przuntek
W
W
Kuhn
D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid*; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000008:administration & dosage*
D012642:Selegiline; D007980:Levodopa; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D002262:Carboxy-Lyases; D006719:Homovanillic Acid